	US 12,134,647 B2
	Binding molecules
Jakub Jaworski, Oxon (GB); Kate Atkin, Oxon (GB); Arnaud Techine, Oxon (GB); Vijaykumar Karuppiah, Oxon (GB); Florence Schlosser, Oxon (GB); Ana Pereira Ribeiro, Oxon (GB); Chandramouli Chillakuri, Oxon (GB); Nathaniel Liddy, Oxon (GB); Andrew Creese, Oxon (GB); and Martin Ebner, Oxon (GB)
Assigned to IMMUNOCORE LIMITED, Oxon (GB)
Filed by Immunocore Limited, Oxon (GB)
Filed on Jan. 5, 2024, as Appl. No. 18/405,910.
Claims priority of application No. 2300227 (GB), filed on Jan. 6, 2023.
Prior Publication US 2024/0228617 A1, Jul. 11, 2024
Int. Cl. C07K 16/00 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)

CPC C07K 16/2809 (2013.01) [A61P 35/00 (2018.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/622 (2013.01)]

22 Claims

1. A binding molecule comprising a TCR alpha chain variable domain and a TCR beta chain variable domain, wherein the binding molecule has the property of binding to PYLGQMINL (SEQ ID NO: 1) in complex with HLA-A24, wherein each of the alpha chain variable domain and the beta chain variable domain comprises FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, where FR is a framework region and CDR is a complementarity determining region, wherein

(a) the alpha chain CDRs have the following sequences:

	CDR1
	(SEQ ID NO: 5)
	SSYSPS,

	CDR2
	(SEQ ID NO: 27)
	YIGNVTLV,

	CDR3
	(SEQ ID NO: 30)
	VVGAPHHNDKII,

and

(b) the beta chain CDRs have the following sequences:

	CDR1
	(SEQ ID NO: 32)
	SGDYS

	CDR2
	(SEQ ID NO: 35)
	YYNAEE

	CDR3
	(SEQ ID NO: 41)
	ASSIWSIGGASSGNLS.